EGFR and neoplasm: For patients without activating mutations in the downstream effectors of the epidermal growth factor receptor (EGFR) pathway and a left‐sided tumour [4], addition of an anti‐EGFR antibody to chemotherapy has shown promising results with median overall survival (OS) of 30–33 months [5, 6].